ATE524196T1 - An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür - Google Patents

An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Info

Publication number
ATE524196T1
ATE524196T1 AT02801760T AT02801760T ATE524196T1 AT E524196 T1 ATE524196 T1 AT E524196T1 AT 02801760 T AT02801760 T AT 02801760T AT 02801760 T AT02801760 T AT 02801760T AT E524196 T1 ATE524196 T1 AT E524196T1
Authority
AT
Austria
Prior art keywords
cancer
associated antigen
antibodies binding
antigen
mpa7
Prior art date
Application number
AT02801760T
Other languages
English (en)
Inventor
Jennie Mather
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE524196T1 publication Critical patent/ATE524196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02801760T 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür ATE524196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32964401P 2001-10-16 2001-10-16
PCT/US2002/033116 WO2003032814A2 (en) 2001-10-16 2002-10-16 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE524196T1 true ATE524196T1 (de) 2011-09-15

Family

ID=23286361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801760T ATE524196T1 (de) 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Country Status (7)

Country Link
US (2) US7148038B2 (de)
EP (1) EP1441766B1 (de)
JP (1) JP4347694B2 (de)
AT (1) ATE524196T1 (de)
CA (1) CA2463927A1 (de)
HK (1) HK1064621A1 (de)
WO (1) WO2003032814A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524196T1 (de) 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
SI1530482T1 (sl) * 2002-07-18 2014-03-31 Helix Biopharma Corp. Uporaba ureaze za inhibiranje rasti rakavih celic
US20050226873A1 (en) * 2003-09-30 2005-10-13 Del Priore Lucian V Medical devices and methods for modulating cell adhesion
PE20090046A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US20080219981A1 (en) * 2004-03-29 2008-09-11 Hideki Shimada Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
JP2010516259A (ja) 2007-01-22 2010-05-20 レイベン バイオテクノロジーズ ヒトがん幹細胞
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5964300B2 (ja) 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
SG10201506959SA (en) * 2010-09-03 2015-10-29 Stemcentrx Inc Novel modulators and methods of use
EP2689787A1 (de) * 2010-09-03 2014-01-29 Stem Centrx, Inc. Neue Modulatoren und deren Verwendung
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
US9567402B2 (en) * 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
WO2015007887A1 (en) * 2013-07-19 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a ligand of hvem and an immunotoxin for use in therapy
WO2015085162A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
TWI707872B (zh) 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
EP3191524A4 (de) 2014-09-12 2018-05-30 The Regents of The University of California Makropinozytosierende menschliche anti-cd46-antikörper und zielgerichtete krebstherapeutika
WO2016123608A2 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
US11612426B2 (en) 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
CN105462935B (zh) * 2016-01-20 2017-08-04 潘世扬 抗卵巢癌单克隆抗体及其应用
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5496550A (en) * 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
DE10299017I2 (de) * 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid.
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5514787A (en) * 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
EP0483247A4 (en) * 1989-07-21 1992-12-09 Washington University Recombinantly produced human membrane cofactor protein (mcp)
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5846715A (en) * 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994015969A1 (en) * 1993-01-14 1994-07-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-hiv antibody and preparation thereof
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) * 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
AU2077197A (en) * 1996-03-18 1997-10-10 Novo Nordisk Biotech, Inc. Polypeptides having phytase activity and nucleic acids encoding same
US6110724A (en) * 1996-10-18 2000-08-29 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
AU2001261259A1 (en) 2000-05-12 2001-11-26 Anil K. Kaul Diagnostic method for screening complement regulatory protein levels
EP1184458A1 (de) * 2000-08-28 2002-03-06 U-BISys B.V. Unterschiedlich exprimierte CD46 Epitope, proteinartige Moleküle die fähig sind daran zu binden, und deren Verwendungen
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
ATE524196T1 (de) * 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
KR20050004263A (ko) * 2002-05-30 2005-01-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 독물학 및 투여량 예측을 위한 동물 모델
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Also Published As

Publication number Publication date
JP4347694B2 (ja) 2009-10-21
HK1064621A1 (en) 2005-02-04
US7148038B2 (en) 2006-12-12
US7744878B2 (en) 2010-06-29
US20030108966A1 (en) 2003-06-12
EP1441766A2 (de) 2004-08-04
EP1441766A4 (de) 2006-03-08
EP1441766B1 (de) 2011-09-14
CA2463927A1 (en) 2003-04-24
US20070128202A1 (en) 2007-06-07
WO2003032814A3 (en) 2003-09-12
WO2003032814A2 (en) 2003-04-24
JP2005511525A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
RS80704A (en) ANTI- av?6.ANTIBODIES
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DE602006013029D1 (de) Anti-egfr-antikörper
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2003064593A3 (en) Antigen panels and methods of using the same
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2003024302A3 (en) Detection and treatment of cancers of breast
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
NO20004250L (no) Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet
WO2004096855A3 (en) Methods utilising g-protein coupled receptor 54
WO2003024304A3 (en) Detection and treatment of cancers of the liver
DE60018964D1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties